연구
교육
솔루션
로그인
KR
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Cyrus Tang Hematology Center,
Cyrus Tang Medical Institute,
Cyrus Tang Hematology Center, Cyrus Tang Medical Institute
Fengchan Li has not added Biography.
If you are Fengchan Li and would like to personalize this page please email our Author Liaison for assistance.
Vascular Semaphorin 7A Upregulation by Disturbed Flow Promotes Atherosclerosis Through Endothelial β1 Integrin.
Arteriosclerosis, thrombosis, and vascular biology 02, 2018 | Pubmed ID: 29269512
Semaphorin 7A promotes endothelial to mesenchymal transition through ATF3 mediated TGF-β2/Smad signaling.
Cell death & disease Aug, 2020 | Pubmed ID: 32826874
Single-cell RNA-seq reveals cellular heterogeneity of mouse carotid artery under disturbed flow.
Cell death discovery Jul, 2021 | Pubmed ID: 34282126
Single-cell transcriptional profiling of human carotid plaques reveals a subpopulation of endothelial cells associated with stroke incidences.
Journal of cellular and molecular medicine Jun, 2022 | Pubmed ID: 35527426
Sema7A protects against high-fat diet-induced obesity and hepatic steatosis by regulating adipo/lipogenesis.
Molecular metabolism Apr, 2023 | Pubmed ID: 36842496
Corrigendum to "Sema7A protects against high-fat diet-induced obesity and hepatic steatosis by regulating adipo/lipogenesis" [Mol Metab. 70 (2023) 101698]∗.
Molecular metabolism Dec, 2023 | Pubmed ID: 37871636
Soochow University
Fengchan Li1,
Zhen Zhu1,
Yun Du1,
Li Zhu1,2,3,
Chaojun Tang1,2,3
1Cyrus Tang Hematology Center, Cyrus Tang Medical Institute, Soochow University,
2Collaborative Innovation Center of Hematology of Jiangsu Province, Soochow University,
3Suzhou Key Laboratory of Thrombosis and Vascular Biology, Soochow University
개인 정보 보호
이용 약관
정책
연락처
사서에게 추천하기
JoVE 뉴스레터
JoVE Journal
연구 방법 컬렉션
JoVE Encyclopedia of Experiments
아카이브
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
교수 리소스 센터
저자
사서
액세스
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유